CLOs on the Move

Five Prime Therapeutics

www.fiveprime.com

 
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.fiveprime.com
  • 111 Oyster Point Boulevard
    South San Francisco, CA USA 94080
  • Phone: 415.365.5600

Executives

Name Title Contact Details
Danielle Shultz
Director and Corporate Counsel Profile
Julie Shah
Executive Director, Associate General Counsel and Assistant Secretary Profile

Similar Companies

PellePharm

We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.

VIRxSYS Corporation

VIRxSYS Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Omicia

Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes. Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal™, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at more than 300 academic and clinical institutions including the NIH, the University of Oxford, the University of Cambridge, Seattle Children’s Research Institute, Institut Pasteur, University of Maryland Institute for Genome Sciences, and UCSF.

Cerapedics

i-FACTOR Peptide Enhanced Bone Graft is a drug/device combination that creates a new category of bone graft technology. Take a moment to review our introduction to i-FACTOR, our Level-1 IDE study and comparative performance sections given below.

Center for Functional Genomics

Center for Functional Genomics is a Rensselaer, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.